microRNA-454-mediated NEDD4-2/TrkA/cAMP axis in heart failure: Mechanisms and cardioprotective implications

Yaowen Wang1, Wei Pan1, Xinyu Bai2

  • 1Department of Cardiology, Chongqing Cardiac Arrhythmias Therapeutic Service Center, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Insights

MicroRNA-454 (miR-454) protects against heart failure by inhibiting NEDD4-2, which prevents TrkA degradation and activates the cAMP pathway, reducing cardiomyocyte apoptosis and myocardial damage.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Heart failure (HF) involves complex molecular mechanisms.
  • The role of microRNAs in HF pathogenesis is an area of active investigation.
  • Understanding specific regulatory axes is crucial for developing therapeutic strategies.

Purpose of the Study:

  • To elucidate the mechanism of miR-454 in heart failure progression.
  • To investigate the interplay between miR-454, NEDD4-2, TrkA, and the cAMP pathway.
  • To determine the therapeutic potential of miR-454 in mitigating cardiac damage.

Main Methods:

  • Established a rat model of heart failure and used H2O2-induced oxidative stress in H9c2 cells.
  • Utilized RT-qPCR, Western blot, dual-luciferase reporter assays, and co-immunoprecipitation.
  • Performed gain/loss-of-function and rescue experiments in vitro and in vivo.

Main Results:

  • miR-454 was downregulated in heart failure and targeted NEDD4-2, reducing its expression.
  • miR-454 inhibited NEDD4-2-mediated ubiquitination and degradation of TrkA.
  • miR-454 activated the cAMP pathway via the NEDD4-2/TrkA axis, suppressing apoptosis and damage.

Conclusions:

  • miR-454 exhibits a cardioprotective role in heart failure.
  • The mechanism involves inhibiting NEDD4-2 to stabilize TrkA and activate the cAMP pathway.
  • Targeting the miR-454/NEDD4-2/TrkA/cAMP axis offers a potential therapeutic strategy for heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
151
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
99
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
158
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
16.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
117